ARTICLE | Clinical News
B244: Phase IIb started
September 26, 2016 7:00 AM UTC
AOBiome began a double-blind, placebo-controlled, U.S. Phase IIb trial to evaluate 4x10 9 colony forming units (CFUs)/mL B244 topical spray administered to the face twice daily for 12 weeks in about 3...